NASDAQ:VRNA - Verona Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.00
  • Forecasted Upside: 230.19 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$6.36
▲ +0.24 (3.92%)

This chart shows the closing price for VRNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Verona Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRNA

Analyst Price Target is $21.00
▲ +230.19% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Verona Pharma in the last 3 months. The average price target is $21.00, with a high forecast of $25.00 and a low forecast of $17.00. The average price target represents a 230.19% upside from the last price of $6.36.

This chart shows the closing price for VRNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Verona Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/4/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/25/2022HC WainwrightReiterated RatingBuy$25.00Low
1/6/2022HC WainwrightReiterated RatingBuy$25.00Medium
9/13/2021HC WainwrightInitiated CoverageBuy$25.00High
6/13/2021BTIG ResearchReiterated RatingBuy$17.00Low
11/30/2020WedbushReiterated RatingBuyLow
8/25/2020Jefferies Financial GroupInitiated CoverageBuy$17.00High
7/22/2020WedbushReiterated RatingBuy$23.00Low
4/21/2020WedbushLower Price TargetOutperform$60.00 ➝ $50.00High
3/31/2020WedbushReiterated RatingBuy$60.00High
2/28/2020WedbushReiterated RatingBuy$60.00Low
2/14/2020WedbushReiterated RatingBuy$60.00N/A
1/14/2020SunTrust BanksBoost Price TargetBuy ➝ Buy$29.00 ➝ $34.00High
1/13/2020WedbushBoost Price TargetOutperform$58.00 ➝ $60.00High
12/13/2019WedbushReiterated RatingBuy$58.00Low
10/15/2019WedbushReiterated RatingBuyLow
9/19/2019WedbushReiterated RatingBuy$58.00High
7/29/2019WedbushReiterated RatingOutperform$58.00High
5/20/2019WedbushSet Price TargetBuy$58.00Low
5/13/2019WedbushReiterated RatingOutperform$56.00 ➝ $58.00Low
4/17/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$17.00High
1/14/2019WedbushReiterated RatingBuyHigh
12/27/2018WedbushSet Price TargetBuy$56.00Low
10/16/2018WedbushSet Price TargetBuy$56.00Low
9/19/2018WedbushReiterated RatingBuy$56.00High
8/10/2018Jefferies Financial GroupReiterated RatingBuy$26.00Low
8/7/2018WedbushSet Price TargetBuy$56.00High
3/27/2018WedbushReiterated RatingOutperform ➝ Outperform$48.00 ➝ $55.00High
3/26/2018SunTrust BanksBoost Price TargetBuy ➝ Buy$26.00 ➝ $37.00High
3/2/2018Stifel NicolausSet Price TargetBuy$25.00Low
2/20/2018Berenberg BankInitiated CoverageBuy ➝ Buy$30.00High
2/13/2018WedbushReiterated RatingOutperform$33.00Low
12/8/2017WedbushReiterated RatingBuy$33.00Low
9/8/2017WedbushReiterated RatingOutperform$33.00Low
5/22/2017Jefferies Financial GroupReiterated RatingBuy$26.00High
5/22/2017WedbushInitiated CoverageOutperform ➝ Outperform$25.00High
5/22/2017SunTrust BanksInitiated CoverageBuy ➝ Buy$26.00High
5/22/2017Stifel NicolausInitiated CoverageBuy ➝ Buy$22.00High
(Data available from 1/26/2017 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022

Current Sentiment

  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Verona Pharma logo
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $6.36
Low: $5.92
High: $6.52

50 Day Range

MA: $5.74
Low: $3.91
High: $7.08

52 Week Range

Now: $6.36
Low: $3.66
High: $9.72

Volume

98,573 shs

Average Volume

105,473 shs

Market Capitalization

$381.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Verona Pharma?

The following sell-side analysts have issued stock ratings on Verona Pharma in the last twelve months: BTIG Research, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for VRNA.

What is the current price target for Verona Pharma?

2 Wall Street analysts have set twelve-month price targets for Verona Pharma in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 242.9%. HC Wainwright has the highest price target set, predicting VRNA will reach $25.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $17.00 for Verona Pharma in the next year.
View the latest price targets for VRNA.

What is the current consensus analyst rating for Verona Pharma?

Verona Pharma currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VRNA will outperform the market and that investors should add to their positions of Verona Pharma.
View the latest ratings for VRNA.

How do I contact Verona Pharma's investor relations team?

Verona Pharma's physical mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The official website for Verona Pharma is www.veronapharma.com.